Prevent return to opioid dependence with most effective treatment. 3-6 months implants.
The main active ingredient of the medicine is naltrexone, which reliably blocks the opiate receptors of the brain for a long time. Due to the effect of Prodetoxon, narcotic substances (opium, heroin, methadone), analgesics based on narcotic substances and their surrogates cease to affect the human body.
Effective treatment procedure for alcohol dependence; produces an extremely negative reaction on consumption of alcohol. 6-9 months implants.
Disulfiram-N block the processing of alcohol in the body by inhibiting acetaldehyde dehydrogenase and causing symptoms of disulfiram-ethanol reaction (DER) include headache, generalized flushing, malaise, dyspnoea, palpitations and vomiting; hypotension and tachycardia are also present.
New medicine for prolonged blockade of cannabinoid CNS receptors. 4-6 months implants.
Prognezol reliably and long-termed affects the cannabinoid receptors of the brain, excluding the consequences of using cannabinoid drugs («silver» and «gold» spices, marijuana, hash) and their surrogates on the body. The main active ingredient is a synthetic of pregnenolone. Due to the low bioavailability of pregnenolone, implantation is the most effective method of application.
Prodetoxon is really a new word in the treatment of drug addiction. I’ve been working as a narcologist for more than 20 years, I’ve always faced the problem of compliance with patients, I had to constantly monitor the taking of medications. Drug addicts are compicated people, they do not always give an account of their actions and, at times, stop taking medication, even the most conciencious patients. Subcutaneous implantation of the drug completely removed this problem.
When nonpharmacologic approaches fail, naltrexone and acamprosate are the drugs of choice for treating patients with moderate to severe alcohol use disorder (AUD), according to a new American Psychiatric Association (APA) practice guideline published in the American Journal of Psychiatry.
Naltrexone and acamprosate are also appropriate for patients who prefer them as an initial treatment choice, the guideline advises.
Despite the availability of evidence-based interventions, fewer than 1 in 10 people in the United States with a 12-month diagnosis of AUD receive treatment, according to the APA. The estimated lifetime prevalence rate for the disorder in the United States is 29%.
“This new guideline is an important step in bringing effective, evidence-based treatments for alcohol use disorder to many more people and in helping address the public health burden of alcohol use,” said Anita Everett, MD, president of the APA.
The guideline also suggests topiramate and gabapentin as other medication options for patients with moderate to severe AUD; although, in most cases, naltrexone and acamprosate should be tried first. Disulfiram, meanwhile, is generally not used as a first-line treatment because it produces physical reactions such as flushing when alcohol is consumed within 12-24 hours of medication use.
The guideline focuses on pharmacologic treatments but states that evidence-based psychotherapeutic treatments, including cognitive-behavioral therapy, 12-step facilitation, and motivational enhancement therapy, play a major role in helping patients with AUD, too. While also acknowledging the benefit of Alcoholics Anonymous and other community-based peer support groups for many patients, the guideline notes that specific recommendations related to these treatments are outside its scope.
The American Psychiatric Association
Original: Treatment of Patients With Alcohol Use Disorder.